

# Conventional versus minimally invasive extracorporeal circulation in patients undergoing cardiac surgery: a randomised controlled trial

|                                        |                                                   |                                                                                                              |
|----------------------------------------|---------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| <b>Submission date</b><br>18/12/2017   | <b>Recruitment status</b><br>No longer recruiting | <input checked="" type="checkbox"/> Prospectively registered<br><input checked="" type="checkbox"/> Protocol |
| <b>Registration date</b><br>18/01/2018 | <b>Overall study status</b><br>Completed          | <input type="checkbox"/> Statistical analysis plan<br><input checked="" type="checkbox"/> Results            |
| <b>Last Edited</b><br>29/02/2024       | <b>Condition category</b><br>Circulatory System   | <input type="checkbox"/> Individual participant data                                                         |

## Plain English summary of protocol

### Background and study aims

Miniaturised heart-lung machines (minimally invasive extracorporeal circulation; MiECC) have been developed with the aim of reducing the number of post-operative complications arising from using conventional heart-lung machines (CECC). Due to the variety of miniaturised systems that have been evaluated, the different types of patients and outcomes investigated, and the poor quality of previous studies, the effectiveness of MiECC in reducing post-operative complications has not been established and most hospitals continue to use CECC. Compared to CECC, using MiECC during cardiac surgery may reduce the proportion of patients having one of several serious postoperative complications (death, heart attack, stroke, gut infarction, severe acute kidney injury, reintubation, tracheostomy, mechanical ventilation for more than 48 hours, or reoperation). In addition, MiECC may reduce the amount of blood products transfused, time to discharge from the cardiac intensive care unit and hospital and the health care resources used during the hospital stay. The aim of this study is to evaluate the MiECC system and to detect if there is a reduction in risks as compared to the CECC.

### Who can participate?

Adults aged 18 to 85 who are undergoing any elective or urgent coronary artery bypass surgery, aortic valve replacement or both using a heart-lung machine without circulatory arrest.

### What does the study involve?

Participants are randomly allocated to one of two groups. Participants in the first group undergo surgery using the MiECC system. Those in the second group undergo surgery using CECC. Participants are followed up twice, at 30 days and at 90 days after surgery to look at the serious adverse events and their health quality of life.

### What are the possible benefits and risks of participating?

The risks of having cardiac surgery are different from person to person, depending on the severity of heart disease, type of operation, age, and current state of health. Both types of heart and lung machines are used currently for heart operations in the NHS. At present, hospitals can choose either machine as there is little evidence to decide which machine is better.

Where is the study run from?

1. Bristol Royal Infirmary (UK)
2. Derriford Hospital (UK)
3. Hammersmith Hospital (UK)
4. Castle Hill Hospital (UK)
5. Royal Papworth Hospital (UK)
6. Aristotle University of Thessaloniki (Greece)
7. Inselspital, Universitätsspital Bern (Switzerland)
8. Universitätsklinikum Ulm (Germany)
9. Klinikum Braunschweig (Germany)
10. Ankara Numune Egitim Arastirma Hastanesi (Turkey)
11. Saud Al Babbain Cardiac Center (Saudi Arabia)

When is the study starting and how long is it expected to run for?

January 2017 to December 2020

Who is funding the study?

British Heart Foundation (BHF) (UK)

Who is the main contact?

Mr Jonathan Evans (Scientific), [comics-trial@bristol.ac.uk](mailto:comics-trial@bristol.ac.uk)

Professor Gianni Angelini – Chief Investigator

Professor Kyriakos Anastasiadis – Principal Investigator, Lead for EU-Countries

Professor Thierry Carrel – Principal Investigator, Lead for Non-EU Countries

## Contact information

### Type(s)

Scientific

### Contact name

Mr Jonathan Evans

### Contact details

Clinical Trials and Evaluation Unit

University of Bristol

Bristol Royal Infirmary

Bristol

United Kingdom

BS2 8HW

+44 117 923 0000

[comics-trial@bristol.ac.uk](mailto:comics-trial@bristol.ac.uk)

### Type(s)

Scientific

### Contact name

Prof Kyriakos Anastasiadis

### Contact details

Aristotle University of Thessaloniki.  
Cardiothoracic Department  
AHEPA University Hospital  
S. Kyriakidi 1  
Thessaloniki  
Greece  
546 36

**Type(s)**

Scientific

**Contact name**

Prof Thierry Carrel

**Contact details**

Inselspital, Universitätsspital Bern  
Herz- und Gefäßchirurgie  
Freiburgstrasse  
Bern  
Switzerland  
CH-3010

**Type(s)**

Scientific

**Contact name**

Prof Andreas Liebold

**Contact details**

Universitätsklinikum Ulm  
Klinik für Herz-, Thorax- und Gefäßchirurgie  
Albert-Einstein-Allee 23  
Ulm  
Germany  
89081

**Type(s)**

Scientific

**Contact name**

Dr Aschraf El-Essawi

**Contact details**

Klinikum Braunschweig  
Klinik für Herz-, Thorax- und Gefäßchirurgie  
Salzdahlumerstrasse 90  
Braunschweig  
Germany  
38126

**Type(s)**

Scientific

**Contact name**

Prof Serdar Gunaydin

**Contact details**

Numune Egitim Arastirma Hastanesi  
Kalp Damar Cerrahisi  
Talatpasa blvd No:5  
Ankara  
Türkiye  
06100

**Type(s)**

Scientific

**Contact name**

Dr Farouk Queida

**Contact details**

Saud Al Babbain Cardiac Center  
Ghirnatah  
5443 King Khalid  
Dammam  
Saudi Arabia  
32245

## **Additional identifiers**

**EudraCT/CTIS number**

Nil known

**IRAS number**

**ClinicalTrials.gov number**

Nil known

**Secondary identifying numbers**

CPMS 36468

## **Study information**

**Scientific Title**

Conventional versus Minimally Invasive extra-corporeal circulation in patients undergoing Cardiac Surgery: a randomised controlled trial

**Acronym**

COMICS

**Study objectives**

The primary hypothesis is that, compared to CECC, using MiECC during cardiac surgery reduces the proportion of patients experiencing post-operative morbidity.

The proposed trial will overcome most limitations of previous trials of MiECC. It will: (a) evaluate MiECC system that meet specified criteria which are used in participating centres; (b) be large enough to influence clinical practice, since it will be able to detect a worthwhile benefit in an outcome relevant to patients, surgeons and health services; (c) include a range of features to prevent bias.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

South West – Central Bristol Research Ethics Committee, 29/11/2017

### **Study design**

Randomized; Interventional; Design type: Treatment, Surgery

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

The patient information sheet can be made available on request email: [comics-trial@bristol.ac.uk](mailto:comics-trial@bristol.ac.uk)

### **Health condition(s) or problem(s) studied**

Cardiac surgery

### **Interventions**

This study is a multi-centre, two-group parallel randomised controlled trial to investigate the effects of using MiECC in all patients having elective or urgent coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or CABG+AVR using extra-corporeal circulation without circulatory arrest. The research objectives are addressed by randomising participants (1:1 ratio) to have surgery using MiECC system or CECC.

Patients undergoing any elective or urgent CABG, AVR, or CABG+AVR, with extra-corporeal circulation and without circulatory arrest are invited to participate. Potential trial participants are identified from operating lists. All potential participants are sent or given an invitation letter and a PIL describing the study.

Randomisation take place as close to surgery as possible and is performed by an authorised member of the local research team not involved in post-operative data collection. Participants and members of the local research team responsible for data collection are blind to the allocation.

The intervention is applied only for the duration of extra-corporeal circulation without circulatory arrest.

Participants are followed up twice, at 30 days and 90 days after surgery: questions elicit information about SAEs experienced since discharge (including readmissions) at 30 days and HRQoL (using the EQ-5D-5L) will be assessed at both times.

## **Intervention Type**

Other

## **Primary outcome measure**

Composite of post-operative serious adverse events (SAEs) are measured using questions to patients during hospital stay and at 30 days post randomisation via a postal or telephone questionnaire. All SAEs that qualify for the primary outcome will be objectively defined and validated. The following events will qualify:

1. Death
2. Myocardial infarction (MI; suspected events will be documented by serum troponin concentrations and electrocardiograph recording (ECG) and adjudicated)
3. Stroke (report of brain imaging (CT or MRI), in association with new onset focal or generalised neurological deficit)
4. Gut infarction (diagnosed by laparotomy or post mortem)
5. AKI Network criteria for stage 3 AKI [16]
6. Reintubation
7. Tracheostomy
8. Mechanical ventilation for >48 hours, including multiple episodes when separated by more than 12 hours
9. Reoperation
10. Percutaneous intervention
11. Sternal wound infection with dehiscence
12. Septicaemia confirmed by microbiology

## **Secondary outcome measures**

1. All-cause mortality is measured using questionnaires 30 days after randomisation
2. Other SAEs are measured using questionnaires 30 days after randomisation
3. Units of RBC transfused up to 30 days after randomisation
4. Other blood products transfused up to 30 days after randomisation
5. Time to discharge from cardiac ICU is measured using patient notes during the index admission
6. Time to discharge from hospital is measured using patient notes following the index admission
7. Delirium in ICU, assessed with the Intensive Care Delirium Screening Checklist (ICDSC) [17] for up to 5 days; this outcome will only be collected in a subset of participating hospitals that have the capability to do so.
8. Health related quality of life is measured using the HRQoL using the EQ-5D-5L [18] up to 90 days after randomisation; responses to this instrument can be mapped on to 'valuations' for the economic evaluation

9. Health and social care resources and associated costs up to 90 days after randomisation are measured using the patient in hospital stay and again at 30 and 90 days post randomisation via a postal or telephone questionnaire

**Overall study start date**

18/01/2017

**Completion date**

01/12/2020

## **Eligibility**

**Key inclusion criteria**

1. Age  $\geq 18$  and  $< 85$  years
2. Undergoing any elective or urgent CABG, AVR surgery, or CABG+AVR surgery, using extra-corporeal circulation without circulatory arrest

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Upper age limit**

85 Years

**Sex**

Both

**Target number of participants**

Planned Sample Size: 3500; UK Sample Size: 650

**Total final enrolment**

1071

**Key exclusion criteria**

1. Requirement for emergency or salvage operation
2. Requirement for major aortic surgery (e.g. aortic root replacement)
3. Contraindication or objection (e.g. Jehovah's Witnesses) to transfusion of blood products
4. Congenital or acquired platelet, red cell or clotting disorders (patients with iron deficient anaemia will not be excluded)
5. Inability to give informed consent for the study (e.g. learning or language difficulties)

**Date of first enrolment**

05/02/2018

**Date of final enrolment**

01/12/2020

## **Locations**

### **Countries of recruitment**

England

Germany

Greece

Saudi Arabia

Switzerland

Türkiye

United Kingdom

### **Study participating centre**

#### **Bristol Royal Infirmary (Lead Centre)**

Bristol Heart Institute

Bristol

United Kingdom

BS2 8HW

### **Study participating centre**

#### **Derriford Hospital**

Derriford Road

Crownhill

Plymouth

United Kingdom

PL6 8DH

### **Study participating centre**

#### **Hammersmith Hospital**

Du Cane Road

Shepherd's Bush

London

United Kingdom

W12 0HS

### **Study participating centre**



**Castle Hill Hospital**

Castle Road  
Cottingham  
United Kingdom  
HU16 5JQ

**Study participating centre****Royal Papworth Hospital**

Papworth Road  
Cambridge Biomedical Campus  
Cambridge  
United Kingdom  
CB2 0AY

**Study participating centre****Aristotle University of Thessaloniki**

Thessaloniki  
Greece  
541 24

**Study participating centre****Inselspital, Universitätsspital Bern**

Freiburgstrasse 18  
Bern  
Switzerland  
3010

**Study participating centre****Universitätsklinikum Ulm**

Albert-Einstein-Allee 23  
Ulm  
Germany  
89081

**Study participating centre****Klinikum Braunschweig**

Celler Str. 38  
Braunschweig  
Germany  
38114

**Study participating centre**

**Ankara Numune Egitim Arastirma Hastanesi**

Hacettepe, Talatpaşa Blv No:44

Ankara

Türkiye

06230

**Study participating centre**

**Saud Al Babbain Cardiac Center**

Ghirnatah

5443 King Khalid

Dammam

Saudi Arabia

32245

## **Sponsor information**

**Organisation**

University of Bristol

**Sponsor details**

Senate House

Tyndall Avenue

Bristol

England

United Kingdom

BS8 1TH

**Sponsor type**

Hospital/treatment centre

**ROR**

<https://ror.org/0524sp257>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

# Results and Publications

## Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal. The protocol can be made available on request email: [comics-trial@bristol.ac.uk](mailto:comics-trial@bristol.ac.uk)

## Intention to publish date

01/12/2021

## Individual participant data (IPD) sharing plan

At the end of the study, once analysed, anonymised datasets generated during the study can be available on request, please contact [bristol-cteu@bristol.ac.uk](mailto:bristol-cteu@bristol.ac.uk).

## IPD sharing plan summary

Available on request

## Study outputs

| Output type                           | Details     | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------------|-------------|--------------|------------|----------------|-----------------|
| <a href="#">Protocol article</a>      | version 3.0 | 12/08/2020   | 27/02/2023 | Yes            | No              |
| <a href="#">Protocol file</a>         |             |              | 20/07/2023 | No             | No              |
| <a href="#">Plain English results</a> |             |              | 21/07/2023 | No             | Yes             |
| <a href="#">Basic results</a>         |             | 29/02/2024   | 29/02/2024 | No             | No              |